Generic Name and Formulations:
Phenoxybenzamine HCl 10mg; caps.
WellSpring Pharmaceuticals, Corp.
Indications for DIBENZYLINE:
Treatment of pheochromocytoma, to control episodes of hypertension and sweating. May use concomitant β-blocker if tachycardia is excessive.
Individualize. Initially 10mg twice daily. Increase dose every other day, usually to 20–40mg 2 or 3 times daily, until optimal dose obtained. Observe patients after each increase before instituting another increase.
Conditions where a fall in BP may be undesirable.
Cerebral or coronary arteriosclerosis. Renal damage. May aggravate respiratory infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant drugs that stimulate both alpha- and beta-adrenergic receptors (eg, epinephrine) may produce exaggerated hypotensive response and tachycardia. Blocks hyperthermia production by levarterenol. Blocks hypothermia production by reserpine.
Alpha adrenergic blocker.
Postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, miosis, GI upset, drowsiness, fatigue. May be carcinogenic (w. long-term use: not recommended).
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine